Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00498004
Status:
TERMINATED
Last Update Posted:
2008-11-04
First Post:
2007-07-06
Brief Title:
Quality of Life QOL in Female Patient With Schizophrenia
Sponsor:
Inje University
Organization:
Inje University
Study Overview
Official Title:
Randomized Open Label 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia
Status:
TERMINATED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
difficult to recruit subject
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to demonstrate clinical and statistical superiority of quetiapine compared to risperidone in Korean version of Heinrichs Quality of Life Scale after 8 weeks trial of drugs
Detailed Description:
Prolactin related adverse events are closely related to patients perception on their illness and quality of life Poor subjective wellbeing induced by prolactin elevation after antipsychotic drug treatment can complicate the clinical outcomes of treatmentQuetiapine has negligible effects on the elevation of prolactin and does not produce hyperprolactinemia related adverse events such as amenorrhea galactorrhea that may disturb quality of life in famel patient In this Randomized Open Label 8-week Study the impact of quetiapine and risperidone on quality of life in female patients with schizophrenia will be compared
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None